Showing 1661-1670 of 2105 results for "".
- Editor's Messagehttps://practicalneurology.com/columns/practice-management/editors-message/31236/Navigating the Shifting Landscape of Medicare Reimbursements in NeurologyIn the December 2006 issue of *Practical Neurology*, Editor-in-Chief Jack Persico addresses the escalating challenges posed by declining Medicare reimbursements and their profound impact on neurological practices. As Medicare r
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31247/Recent developments in the treatment of high-grade carotid stenosis have intensified interest in carotid artery stenting (CAS) as an alternative to the traditional carotid endarterectomy (CEA). The FDA has approved CAS for patients with symptomatic carotid stenosis who are deemed high-risk for conve
- Epilepsy Essentialshttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/PN0806Epilepsy-pdf/31282/Alcohol and Drug-Induced Seizures: Implications for Neurological PracticeSeizure activity related to alcohol and drug use remains a significant concern in neurology, affecting both acute management and long-term treatment strategies. Heavy alcohol consumption, prevalent in up to 20% of individuals,
- Editor's Messagehttps://practicalneurology.com/columns/practice-management/editors-message/31293/Practical Neurology’s Esteemed Editorial and Contributing Boards Showcase Leading Expertise in Neurological MedicinePractical Neurology proudly features a distinguished team of medical professionals serving on its Editorial Advisory Board, Editorial Board, and as Contributing Editors. This collectiv
- Pathological Gambling and Other Impulse Control Disorders in Parkinson'shttps://practicalneurology.com/diseases-diagnoses/movement-disorders/pn0706feaGambling-pdf/31296/Impulse Control Disorders in Parkinson’s Disease: Association with Dopamine Agonist TherapyImpulse Control Disorders (ICDs), encompassing pathological gambling (PG), compulsive sexual behavior, and compulsive buying, are increasingly recognized in patients with Parkinson’s Disease (PD). Recent studi
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31291/Recent advancements in stroke prevention have been scrutinized through pivotal clinical trials, providing critical insights for healthcare professionals. Last month, the ACTIVE, CHARISMA, and MATCH trials collectively assessed the efficacy of combining aspirin with clopidogrel in over 25,000 stroke
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31309/Recent large-scale trials have cast doubt on the efficacy of combination antiplatelet therapies, such as clopidogrel (Plavix) plus aspirin or dipyridamole plus aspirin (Aggrenox), for secondary stroke prevention in high-risk patients. Historically, these combinations were favored over aspirin alone
- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/31305/Practical Neurology June 2006 Highlights Key Advances in Neurological TreatmentsIn June 2006, several significant developments emerged in the field of neurology, offering new insights and treatment options for various neurological conditions. The FDA reinstated natalizumab (Tysabri) for multiple scl
- Back to the Books: Updating Our Approach to Parkinson'shttps://practicalneurology.com/diseases-diagnoses/movement-disorders/PN0606ParkinsonsGuidelines-pdf/31307/The American Academy of Neurology’s Quality Standards Subcommittee has introduced four new practice parameters for the diagnosis and management of Parkinson’s disease (PD), marking a significant advancement for healthcare professionals in the field. These guidelines are essential for general neurolo
- Income Survey: Surviving the Storm, Steering to Safetyhttps://practicalneurology.com/columns/practice-management/income-survey-surviving-the-storm-steering-to-safety/31315/Income Trends and Challenges in Neurology PracticesA May 2006 issue of *Practical Neurology* presents findings from the fifth annual income survey, highlighting evolving financial dynamics within neurology practices. Over the past decade, neurologists have grappled with declining third-party reimbur